Dear Commons Community,

This week’s Science has an article that questions the decision by which the FDA entered into agreement with the company, Gilead Sciences, to develop the drug remdesivir to treat COVID-19.  Essentially the FDA and the European Union entered into the agreement just after a major study found that remdesivir had little value.  It is indicative of how careful our government needs to be NOT to rush the development of drugs needed to combat COVID.

The entire article is below.

Tony

This entry is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license.